Trialjectory, which develops a new technology service to match cancer patients with clinical contests, had given rise to $ 2.7 million to finance its continued growth.
Led by Contour Venture Partners, the new financing will be used to accelerate Trialjectory’s operations by lending more clinical ordeals for different cancer types and expanding the company’s outreach to caregivers, pharmaceutical companies and patients, the company said.
“As cancer is the second leading cause of death for Americans — with thousands of new cases diagnosed every year — having access to advanced treatment alternatives is a necessity , not a privilege, as new contests stipulate better outcomes to patients, ” said Tzvia Bader, Trialjectory chief executive and co-founder. “What’s more, one of the top deterrents that oncologists face today is the lack of clinical trial access for patients, which is due to the availability of more treatment alternatives overall. Additionally, it is a very complex process to match the freedom patient with the liberty management, especially with the rise of personalized medicine.”
The company currently patronage trials for breast cancer, colon cancer, bladder cancer, melanoma and myelodysplastic syndromes.
Trialjectory’s software was trained to seek out keywords in unstructured care descriptions and extracting relevant data. Its software then radicals that report into clusters and standardizes the information to create a database that highlights patient qualities that would be appropriate for clinical trials.
Patients are then parallelled to the clinical experiments after filling out a questionnaire.
” Trialjectory’s duty — driven by a highly experienced handling squad, comprised of both oncology and technological sciences experts — is obstructing and reshaping how we think about traditional cancer care today, ” concluded Bob Greene, from Contour Venture Partners. “Even more important, it is empowering patients to take back control of their management, and we look forward to watching Trialjectory’s platform continue to grow quickly. We believe that the company has the potential to become a go-to resource for the global medical community to help doctors require personalized, accorded care options to cases in need everywhere.”
Read more: feedproxy.google.com